Effects of inhaled HFA beclomethasone on pulmonary function and symptoms in patients with chronic obstructive pulmonary disease

Chronic obstructive pulmonary disease is characterized by progressive airflow limitation and pulmonary inflammation. Inhaled corticosteroids (ICS) have been shown to be effective in the reduction of the number of exacerbations and the rate of deterioration in health status in patients with more adva...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Respiratory medicine 2005-11, Vol.99 (11), p.1418-1424
Hauptverfasser:	John, Matthias, Bosse, Susanne, Oltmanns, Ute, Schumacher, Axel, Witt, Christian
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Inhalation Anti-Inflammatory Agents - therapeutic use Asthma Beclomethasone - therapeutic use Biological and medical sciences Bones, joints and connective tissue. Antiinflammatory agents Cell culture Chronic obstructive pulmonary disease, asthma COPD Cross-Over Studies Cytokines Cytokines - blood Disease Double-Blind Method Drug therapy Enzyme-Linked Immunosorbent Assay Female Forced Expiratory Volume - drug effects Glucocorticoids - therapeutic use HFA 134 beclomethason Humans Hydrocortisone - blood Hyperinflation Inhaled corticosteroids Lung - drug effects Male Medical sciences Middle Aged Monocytes - drug effects Monocytes - secretion Mortality Pharmacology. Drug treatments Pneumology Pulmonary Disease, Chronic Obstructive - blood Pulmonary Disease, Chronic Obstructive - drug therapy Quality of Life Steroids Thyroid diseases
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Chronic obstructive pulmonary disease is characterized by progressive airflow limitation and pulmonary inflammation. Inhaled corticosteroids (ICS) have been shown to be effective in the reduction of the number of exacerbations and the rate of deterioration in health status in patients with more advanced chronic obstructive pulmonary disease (COPD). Therefore current international guidelines recommend ICS for patients with severe COPD (FEV 1
ISSN:	0954-6111 1532-3064
DOI:	10.1016/j.rmed.2005.03.034